• Spirocyclic POM Analogues Target MmpL3 in TB

  2026-09-16

  This 2024 Bioorganic Chemistry study developed spirocyclic phenyl oxazole methyl derivatives and identified compound 5c as an active anti-tubercular lead against Mycobacterium tuberculosis and drug-resistant clinical isolates. Genetic resistance mapping, docking, ADME, pharmacokinetic, and THP-1 cytotoxicity data together support MmpL3 as the likely target and provide a foundation for further optimization.

• DOPE Workflows for Delivery and Fungal Assays

  2026-09-16

  1,2-Dioleoyl-sn-glycero-3-PE (DOPE) is both an endosomal-fusion helper for nucleic acid delivery and a practical phosphatidylethanolamine rescue reagent for fungal developmental assays. This guide connects formulation, conidial ferroptosis experiments, solvent handling, and troubleshooting without treating a rescue result as proof of a single molecular target.

• CP-673451: ATRX-Aware PDGFR Research Strategy

  2026-09-15

  CP-673451 is a selective PDGFRα/β inhibitor for connecting receptor engagement with ATRX-aware glioma, angiogenesis, and xenograft experiments. This article presents a genotype-informed assay strategy that separates direct target inhibition from downstream tumor phenotypes.

• 3D Collagen Microtissues for Cancer Drug Testing

  2026-09-15

  The reference study adapts modular tissue engineering to create free-floating collagen microtissues containing triple-negative breast cancer cells. These constructs reproduced hypoxia, stemness-associated phenotypes, and clinically relevant treatment resistance while remaining comparatively practical to fabricate, offering a useful bridge between conventional monolayers and more complex tumor models.

• Structure-Based NSP15 Inhibitor Discovery

  2026-09-14

  The reference study used structure-based virtual screening and molecular dynamics to prioritize natural products against the SARS-CoV-2 endoribonuclease NSP15. Thymopentin and oleuropein formed the most stable computationally predicted complexes, providing a rational starting point for biochemical validation rather than evidence of clinical antiviral efficacy.

• Cas9 mRNA for Mechanistic Neurodegeneration Research

  2026-09-14

  A translational framework for using EZ Cap™ Cas9 mRNA (5-moUTP) in CRISPR-Cas9 genome editing studies informed by evidence connecting Fyn, Stat3, NF-κB, microglia activation, and dopaminergic neuron loss in zebrafish. The article distinguishes biological evidence from product-specific claims and outlines a disciplined path from target validation to preclinical research.

• Rhodamine 123: From Efflux Signal to Translation

  2026-09-13

  Rhodamine 123 is more than a fluorescent readout: it is a live-cell lens on transporter biology. This thought-leadership article explains how Rhodamine 123 (chloride) can strengthen ABCB1/MDR1 studies, contextualize ABCG2-focused findings such as marein-mediated chemosensitization, and guide translational assay design without overstating what fluorescence alone can prove.

• LACTB, Mitochondrial Remodeling, and Apoptosis

  2026-09-12

  Kamerkar and colleagues identify LACTB as a regulator of apoptosis-induced inner mitochondrial membrane remodeling, linking a tumor-suppressive protein to cytochrome c mobilization without altering BAX or Drp1 recruitment. Their cell-based, imaging, biochemical, and membrane-reconstitution experiments suggest that LACTB acts at the cristae-remodeling stage of apoptosis and provide a framework for separating outer-membrane permeabilization from downstream mitochondrial architecture.

• Epalrestat: Aldose Reductase Inhibitor Workflows

  2026-09-11

  Epalrestat supports mechanism-driven studies spanning polyol pathway inhibition, diabetic neuropathy research, and neuroprotection in Parkinson’s disease models. This practical guide covers stock preparation, assay design, KEAP1/Nrf2 validation, and troubleshooting for reproducible oxidative stress research.

• Alternariol Workflows for Mycotoxin Research

  2026-09-11

  Use AOH as a controlled probe for hepatic stellate-cell activation, apoptosis, cytoskeletal disruption, and cytochrome P450 metabolism. This practical guide combines reproducible dosing, mechanism-focused controls, and troubleshooting strategies for translating Alternaria toxin findings into defensible assays.

• 10 mM dNTP Mixture for PCR and LNP Studies

  2026-09-10

  The 10 mM dNTP mixture provides a controlled nucleotide input for PCR, qPCR, sequencing preparation, and DNA reporter workflows. Paired with the reference study’s intracellular trafficking model, it helps separate DNA production quality from the effects of lipid composition and cholesterol on delivery.

• Thioredoxin Control of CHK1 Inhibitor Sensitivity

  2026-09-10

  This study identifies thioredoxin 1 as a determinant of CHK1 inhibitor sensitivity in non-small cell lung cancer and links that phenotype to redox control of ribonucleotide reductase. Its findings provide a mechanistic basis for combining replication-stress inhibitors with thioredoxin-system perturbation while highlighting the need for tumor-selective strategies that limit toxicity.

• PEP, cGAS–STING, and Healthy Aging

  2026-09-09

  A 2026 Nature Aging study identifies phosphoenolpyruvate (PEP) as an endogenous metabolic brake on cGAS–STING-driven inflammation. Longitudinal profiling, mouse perturbation experiments, human association data, and binding analyses connect PEP to inflammaging, healthy aging, and neuroinflammation while highlighting important limits for translation.

• Netarsudil (AR-13324) Assay Workflow Guide

  2026-09-09

  This scenario-based guide shows how Netarsudil (AR-13324), SKU B7807, can improve interpretation of viability, proliferation, cytotoxicity, and cytoskeletal assays. It connects ROCK biology with formulation, siRNA codelivery, solvent control, and practical product-selection decisions.

• Schwartz 2022: Measuring Drug Responses in Cancer

  2026-09-08

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of in vitro drug response. This framework encourages cancer researchers to measure both outcomes over time rather than treating a single viability score as a complete description of drug activity.

8500 records 1/567 page Next 12345 下5页 Last page